Philippe Bégin, AAAAI 2021: Epicutaneous Immunotherapy for Peanut Allergy

We were delighted to catch up with Philippe Bégin (CHU Sainte-Justine, Montréal, Canada) to discuss the use of epicutaneous immunotherapy for peanut allergy.

The abstract entitled ‘Reduction in Severity Following 12 Months of Epicutaneous Immunotherapy for Peanut Allergy‘ (ABSTRACT NUMBER: 342) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.

Questions:

1. What are the pros and cons of oral immunotherapy and epicutaneous immunotherapy for peanut allergy? (0:13)
2. Could you give us a brief overview of the clinical development of epicutaneous immunotherapy for peanut allergy? (3:37)
3. What are the future directions of immunotherapy for peanut allergy? (4:41)

Disclosures: Philippe Bégin is the clinical trial investigator for DBV technology products.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of AAAAI 2021 (Virtual).